My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 119

    1.

    Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S.

    Shearer A, Scuffham P, Gordois A, Oglesby A.

    Diabetes Care. 2003 Aug;26(8):2305-10.PMID: 12882853 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The health care costs of diabetic peripheral neuropathy in the US.

    Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA.

    Diabetes Care. 2003 Jun;26(6):1790-5.PMID: 12766111 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.

    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA.

    Curr Med Res Opin. 2004 Aug;20 Suppl 1:S5-26.PMID: 15324513 [PubMed - indexed for MEDLINE]Related articles

    4.

    A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

    Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A.

    Pharmacoeconomics. 2007;25(1):39-54. Erratum in: Pharmacoeconomics. 2007;25(3):237. PMID: 17192117 [PubMed - indexed for MEDLINE]Related articles

    5.

    Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations.

    Ragnarson Tennvall G, Apelqvist J.

    Diabetologia. 2001 Nov;44(11):2077-87.PMID: 11719840 [PubMed - indexed for MEDLINE]Related articles

    6.

    Disease progression and cost of insulin dependent diabetes mellitus: development and application of a simulation model.

    Tomar RH, Lee S, Wu SY, Klein R, Klein BE, Moss SE, Fryback DG, Tollios JL, Sainfort F.

    J Soc Health Syst. 1998;5(4):24-37.PMID: 9785295 [PubMed - indexed for MEDLINE]Related articles

    7.

    Model-based evaluation of diabetic foot prevention strategies in Austria.

    Rauner MS, Heidenberger K, Pesendorfer EM.

    Health Care Manag Sci. 2005 Nov;8(4):253-65. Review.PMID: 16379409 [PubMed - indexed for MEDLINE]Related articles

    8.

    Cost of managing complications resulting from type 2 diabetes mellitus in Canada.

    O'Brien JA, Patrick AR, Caro JJ.

    BMC Health Serv Res. 2003 Mar 21;3(1):7.PMID: 12659641 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study.

    Young MJ, Breddy JL, Veves A, Boulton AJ.

    Diabetes Care. 1994 Jun;17(6):557-60.PMID: 8082524 [PubMed - indexed for MEDLINE]Related articles

    10.

    The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy.

    Currie CJ, Poole CD, Woehl A, Morgan CL, Cawley S, Rousculp MD, Covington MT, Peters JR.

    Diabet Med. 2007 Feb;24(2):187-94.PMID: 17257282 [PubMed - indexed for MEDLINE]Related articles

    11.

    Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis.

    Ortegon MM, Redekop WK, Niessen LW.

    Diabetes Care. 2004 Apr;27(4):901-7.PMID: 15047646 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Quantitative assessment of diabetic peripheral neuropathy with use of the clanging tuning fork test.

    Oyer DS, Saxon D, Shah A.

    Endocr Pract. 2007 Jan-Feb;13(1):5-10.PMID: 17360294 [PubMed - indexed for MEDLINE]Related articles

    13.

    Economic costs of diabetes in the U.S. In 2007.

    American Diabetes Association.

    Diabetes Care. 2008 Mar;31(3):596-615. Review. Erratum in: Diabetes Care. 2008 Jun;31(6):1271. PMID: 18308683 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    A preventative foot care programme for people with diabetes with different stages of neuropathy.

    Calle-Pascual AL, Durán A, Benedí A, Calvo MI, Charro A, Diaz JA, Calle JR, Gil E, Marañes JP, Cabezas-Cerrato J.

    Diabetes Res Clin Pract. 2002 Aug;57(2):111-7.PMID: 12062856 [PubMed - indexed for MEDLINE]Related articles

    15.

    Vibration perception threshold--a valuable assessment of neural dysfunction in people with diabetes.

    Garrow AP, Boulton AJ.

    Diabetes Metab Res Rev. 2006 Sep-Oct;22(5):411-9. Review.PMID: 16741996 [PubMed - indexed for MEDLINE]Related articles

    16.

    Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.

    Watkins JB, Minshall ME, Sullivan SD.

    J Manag Care Pharm. 2006 Nov-Dec;12(9):726-35.PMID: 17249905 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    A model to analyse costs and benefit of intensified diabetic foot care in Austria.

    Habacher W, Rakovac I, Görzer E, Haas W, Gfrerer RJ, Wach P, Pieber TR.

    J Eval Clin Pract. 2007 Dec;13(6):906-12.PMID: 18070261 [PubMed - indexed for MEDLINE]Related articles

    18.

    The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.

    Persson U, Willis M, Odegaard K, Apelqvist J.

    Value Health. 2000 Nov-Dec;3 Suppl 1:39-46.PMID: 16464208 [PubMed - indexed for MEDLINE]Related articles

    19.

    Is diabetic foot care efficacious or cost effective?

    Armstrong DG.

    Ostomy Wound Manage. 2001 Apr;47(4):28-32.PMID: 11890086 [PubMed - indexed for MEDLINE]Related articles

    20.

    A comparison of the neurothesiometer and biothesiometer for measuring vibration perception in diabetic patients.

    Young MJ, Every N, Boulton AJ.

    Diabetes Res Clin Pract. 1993 May;20(2):129-31.PMID: 8375265 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity